Safety and efficacy of pimecrolimus cream 1% in the daily practice: Results of a patient self-observation study in patients with atopic dermatitis;Sicherheit und wirksamkeit von pimecrolimus-creme 1% in der täglichen praxis: EL PASO - Ergebnisse einer anwendungsbeobachtung bei patienten mit atopischer dermatitis

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 10, 2007, Pages 908-914

  Luger, Thomas A ^a   Gollnick, Harald ^b   Schwennesen, Thomas ^c   Bextermöller, Raphael ^d   Freytag, Siegfried ^e   Bräutigam, Matthias ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b University Clinic for Dermatology and Venerology   (Germany)

^c Neurodermitiker Bund   (Germany)

^d Novartis Pharma GmbH   (Germany)

^e TNS Healthcare GmbH   (Germany)

Author keywords

Atopic eczema; Eczema; Pimecrolimus; Pruritus

Indexed keywords

ANTIHISTAMINIC AGENT; PIMECROLIMUS; STEROID;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; ATOPIC DERMATITIS; CHICKENPOX; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHEMA; FEMALE; HERPES SIMPLEX; HUMAN; IMPETIGO; INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SELF EVALUATION; SIDE EFFECT; SKIN BURNING SENSATION; SKIN MANIFESTATION; SKIN PRURITUS; SKIN REDNESS; SUPERINFECTION; SYMPTOM; TINEA; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 35148852327     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06510.x     Document Type: Article

References (18)

1. Knoell KA, Greer KE. Atopic Dermatitis. Pediatr Rev 1999 20 : 46 51.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 160.
3. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003 112 : S118 127.
4. Bornhovd EC, Burgdorf HC, Walter HC, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opinion Invest Drugs 2002 3 : 708 712.
5. Tomi NS, Luger T. The treatment of atopic dermatitis with topical immuno-modulators. Clinics in Dermatology 2003 21 : 215 224.
6. Burkhart CN, Gottwald L, Nelson L. Tacrolimus and Pimecrolimus: Revolutionary new topical immunomodula-tors for skin disorders. International Pediatrics 2004 19 : 7 13.
7. Graham-Brown RAC, Grassberger M. Pimecrolimus: A review of preclinical and clinical data. Int J Clin Pract 2003 57 : 319 327.
8. Grassberger M, Steinhoff M, Schneider D, Luger T. Pimecrolimus - an anti-inflammatory drug targeting the skin. J Exp Dermatology 2004 13 : 721 730.
9. Eichenfield LF, Beck L. Elidel (pi-mecrolimus) cream 1%: a non-stero-idal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003 111 : 1154 1168.
10. Wellington K, Noble N. Pimecrolimus: A review of its use in atopic dermatitis. Am J Clin Dermatol 2004 5 : 479 495.
11. Gupta AK, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol 2003 17 : 493 503.
12. Kapp A, Papp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter P, Gulliver W, Paul C, Molloy S, Barbier N, Hultsch T, de Prost Y. Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 2002 110 : 277 284.
13. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Graeber M, Cherill R, DeProst Y for the free (children) multicenter investigator group. Efficacy and safety of pi-mecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : e2.
14. Meurer M, Fartasch M, Albrecht G, Landthaler M, Sterry W, Ruzicka T, Altmeyer PJ, Weidinger G, Bräutigam M for the CASM-DE-01 Study Group. Long-term efficacy and safety of pi-mecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004 208 : 365 372.
15. Papp K, Staab D, Harper J, Potter P, Puig L, Ortonne JP, Molloy S, Barbier N, Paul C. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol 2004 43 : 978 983.
16. Papp KA, Werfel T, Fölster-Holst R, Ortonne JP, Potter PC, De Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants: a 2-year study. J Am Acad Dermatol 2005 52 : 240 246.
17. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, deProst Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006 117 : e118-28.
18. Sunderkötter C, Weiss JM, Bextermöl-ler R, Löffler H, Schneider D. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pi-mecrolimus: Positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges. 2006 4 (4 301 306.